Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M136Revenue (TTM) $M1.7Net Margin (%)-1,177.2Altman Z-Score-3.4
Enterprise Value $M103EPS (TTM) $-0.7Operating Margin %-1,189.5Piotroski F-Score2
P/E(ttm)--Beneish M-Score7.3Pre-tax Margin (%)-1,186.7Higher ROA y-yN
Price/Book5.110-y EBITDA Growth Rate %--Quick Ratio8.6Cash flow > EarningsY
Price/Sales69.85-y EBITDA Growth Rate %--Current Ratio8.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-359.5ROA % (ttm)-65.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-91.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M34.2ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PSDV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PSDVKen Fisher 2015-09-30 Buy $3.49 - $4.47
($3.92)
$ 3.982%New holding12,057
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PSDV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PSDV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ross Leonard SVice President, Finance 2016-01-04Sell5,000$4.7-15.32view
Ross Leonard SVice President, Finance 2015-12-22Sell33,950$5.39-26.16view
Ashton PaulPresident & CEO 2015-12-22Sell120,000$5.39-26.16view
Ross Leonard SVice President, Finance 2015-12-01Sell1,050$4.06-1.97view
Ross Leonard SVice President, Finance 2015-08-03Sell5,000$4.05-1.73view
Ashton PaulPresident & CEO 2014-10-01Sell10,000$4.27-6.79view
Ashton PaulPresident & CEO 2014-09-02Sell10,000$4.78-16.74view
Ashton PaulPresident & CEO 2014-08-01Sell10,000$4.37-8.92view
Ashton PaulPresident & CEO 2014-07-01Sell10,000$4.32-7.87view
Ashton PaulPresident & CEO 2014-06-19Sell7,000$4-0.5view

Quarterly/Annual Reports about PSDV:

    News about PSDV:

    Articles On GuruFocus.com
    Weekly CEO Sales Highlight: pSivida Corp., Equity Residential, Ciena Corp., Sabre Corp. Dec 28 2015 
    pSivida Ltd. Reports Operating Results (10-Q) Feb 10 2011 
    pSivida Ltd. Reports Operating Results (10-Q) Nov 09 2010 
    pSivida Ltd. Reports Operating Results (10-K) Sep 27 2010 
    pSivida Ltd. Reports Operating Results (10-Q) May 13 2010 
    pSivida Ltd. Reports Operating Results (10-Q) Feb 12 2010 
    pSivida Ltd. Reports Operating Results (10-Q) Nov 13 2009 
    pSivida Ltd. Reports Operating Results (10-K) Sep 25 2009 
    pSivida Ltd. Reports Operating Results (10-Q) May 13 2009 
    pSivida Ltd. Reports Operating Results (10-Q) Feb 11 2009 

    More From Other Websites
    Topline Results from First Phase 3 Trial of pSivida’s Medidur™ Presented at ASRS Annual Meeting Aug 15 2016
    Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter... Aug 09 2016
    Primary Endpoint Met in pSivida’s Utilization Study of New Medidur™ Inserter with Smaller... Aug 09 2016
    pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer Aug 03 2016
    pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer Aug 03 2016
    pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for... Aug 01 2016
    pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for... Aug 01 2016
    pSivida Corp.: Strong price momentum but will it sustain? Jul 27 2016
    pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12... Jul 27 2016
    pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12... Jul 27 2016
    ETF’s with exposure to pSivida Corp. : July 20, 2016 Jul 20 2016
    Data Shows pSivida’s Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug... Jul 20 2016
    PSIVIDA CORP. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Regulation FD... Jul 18 2016
    pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility Jul 15 2016
    pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility Jul 15 2016
    Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for... Jul 14 2016
    Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur® Fully Controlled Uveitis for... Jul 14 2016
    pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™... Jul 08 2016
    pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™... Jul 08 2016
    pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release... Jul 05 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)